- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07793838
Metformin Effects on Metabolic, Vitamin B12, Iron, Erythropoietin, and Hematological Parameters in Women With PCOS (MET-PCOS)
The Effects of Metformin Therapy on Changes in Metabolic, Vitamin B12, Iron Status, Erythropoietin, and Hematological Parameters Among Women With Polycystic Ovary Syndrome: A Double-Blind Randomized Controlled Trial
This double-blind, placebo-controlled, parallel-group randomized controlled trial evaluated changes in metabolic, vitamin B12, iron-status, erythropoietic, and hematological parameters among women with polycystic ovary syndrome (PCOS) receiving metformin therapy.
Women aged 18-40 years with a diagnosis of PCOS confirmed by a specialist in Obstetrics and Gynecology were randomly assigned in a 1:1 ratio to either a metformin intervention group or a matching placebo group. Participants in the metformin group received a total daily dose of 1500 mg metformin, administered in three divided doses with meals, while participants in the control group received a matching placebo. Both groups continued to receive routine clinical care.
Clinical and laboratory assessments were performed at baseline, 3 months, and 6 months. The study evaluated metabolic measures, including fasting blood glucose, serum insulin, HOMA-IR, total cholesterol, triglycerides, LDL-C, HDL-C, and body mass index. Iron-status measures included serum iron, total iron-binding capacity, ferritin, and transferrin saturation. Serum vitamin B12 and erythropoietin were also assessed, together with hematological parameters including hemoglobin, hematocrit, red blood cell indices, white blood cell counts and differential counts, and platelet count.
The study enrolled 400 participants, with 200 participants initially allocated to each treatment group. After loss to follow-up, 300 participants completed the required assessments and were included in the final longitudinal analysis, with 150 participants in each group.
The study was designed to characterize longitudinal changes in metabolic, nutritional, iron-related, erythropoietic, and hematological parameters during six months of metformin therapy in women with PCOS.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
Polycystic ovary syndrome (PCOS) is a common and heterogeneous endocrine and metabolic disorder characterized by reproductive, endocrine, and metabolic abnormalities. Insulin resistance, hyperinsulinemia, dyslipidemia, excess weight, and disturbances in reproductive function are important components of the PCOS phenotype. Metformin is an insulin-sensitizing medication widely used to address metabolic abnormalities associated with PCOS.
This double-blind, placebo-controlled, parallel-group randomized controlled trial was designed to evaluate longitudinal changes in metabolic, vitamin B12, iron-status, erythropoietic, and hematological parameters among women with PCOS during six months of metformin therapy. The study also examined selected associations among demographic, clinical, reproductive, familial, metabolic, vitamin B12, iron-status, erythropoietic, and hematological characteristics.
Women aged 18-40 years with PCOS confirmed by a specialist in Obstetrics and Gynecology were eligible for participation. Participants were excluded if they had chronic hemolytic anemia, chronic kidney disease, endocrine disorders other than PCOS, hepatic disorders, metabolic disorders, cardiovascular disease, or other concurrent medical conditions that could influence glucose metabolism, iron status, vitamin B12, erythropoietin, or hematological parameters. Women who had received insulin-sensitizing agents, iron supplementation, hormonal therapy, vitamin B12 supplementation, or other medications known to substantially affect the study outcomes during the predefined period before enrollment were also excluded.
Following baseline assessment, eligible participants were randomly allocated in a 1:1 ratio using a computer-generated random allocation sequence to either the metformin intervention group or the matching placebo group. Participants in the intervention group received metformin at a total daily dose of 1500 mg, administered in three divided doses with meals. Participants in the control group received a corresponding matching placebo according to the same administration schedule. Both groups continued to receive routine clinical care.
The double-blind design was maintained throughout the study. Participants were blinded to treatment allocation, and investigators involved in participant assessment and outcome evaluation were also blinded to treatment assignment. Matching preparations were used to minimize the possibility of identifying treatment allocation based on appearance.
Clinical, anthropometric, biochemical, iron-status, vitamin B12, erythropoietic, and hematological assessments were performed at three predefined time points: baseline, 3 months, and 6 months. Metabolic assessments included body mass index, fasting blood glucose, serum insulin, HOMA-IR, total cholesterol, triglycerides, LDL-C, and HDL-C. Iron-status assessments included serum iron, total iron-binding capacity, ferritin, and transferrin saturation. Serum vitamin B12 and erythropoietin were also assessed. Hematological assessments included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width, white blood cell count, lymphocytes, neutrophils, eosinophils, basophils, monocytes, and platelet count.
The study was conducted in obstetrics and gynecology clinics affiliated with the Ministry of Health in Jordan. The study period extended from August 2025 to February 2026. A total of 400 women were initially enrolled and randomly allocated, with 200 participants assigned to each treatment group. During the six-month follow-up period, 100 participants did not complete the required assessments, leaving 300 participants in the final longitudinal analysis, comprising 150 participants in the metformin group and 150 participants in the matching placebo group.
No additional structured educational, behavioral, lifestyle, or self-management intervention was introduced as part of the study protocol. Participants continued to receive routine clinical care. Lifestyle behaviors, including physical activity, dietary intake, and adherence to lifestyle recommendations, were not systematically quantified using validated assessment instruments.
Longitudinal changes across baseline, 3 months, and 6 months were evaluated using repeated-measures analysis of variance. Associations between selected continuous variables were examined using Pearson's correlation coefficient when appropriate, while Spearman's rank-order correlation coefficient was used for ordinal variables or variables that did not meet the assumptions required for Pearson correlation. Correlation analyses were considered exploratory and hypothesis-generating because multiple associations were examined.
The study received ethical approval from the Ethical Board of the Jordanian Ministry of Health, Amman, Jordan (Approval No. 99923), and the Institutional Review Board of Al-Ahliyya Amman University (Approval No. 2026-2025/30/1). Written informed consent was obtained from all participants before enrollment. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki.
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- 4. fázis
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Amman, Jordánia, 009627
- obstetrics and gynecology clinics affiliated with the Ministry of Health in Jordan،
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Women aged 18-40 years.
- Diagnosis of polycystic ovary syndrome (PCOS) confirmed by a specialist in Obstetrics and Gynecology.
- Eligible participants who met the study requirements and provided written informed consent.
Exclusion Criteria:
- Chronic hemolytic anemia.
- Chronic kidney disease.
- Endocrine disorders other than PCOS.
- Hepatic disorders.
- Metabolic disorders.
- Cardiovascular disease.
- Other concurrent medical conditions that could influence glucose metabolism, iron status, vitamin B12, erythropoietin, or hematological parameters.
- Previous use of insulin-sensitizing agents, iron supplementation, hormonal therapy, vitamin B12 supplementation, or other medications known to substantially affect glucose metabolism, iron metabolism, erythropoietin levels, or hematological parameters during the predefined period before enrollment.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Egyetlen
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Metformin Intervention Group
Participants assigned to the metformin intervention group received metformin at a total daily dose of 1500 mg, administered in three divided doses with meals, for six months in addition to routine clinical care.
Clinical and laboratory assessments were performed at baseline, 3 months, and 6 months.
|
Metformin was administered at a total daily dose of 1500 mg in three divided doses with meals for six months.
|
|
Placebo Comparator: Matching Placebo Group
Participants assigned to the matching placebo group received a corresponding matching placebo according to the same administration schedule for six months in addition to routine clinical care.
Clinical and laboratory assessments were performed at baseline, 3 months, and 6 months.
|
A matching placebo was administered according to the same schedule as the metformin intervention for six months.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Longitudinal change in serum iron
Időkeret: Baseline, 3 months, and 6 months
|
Change in serum iron from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in total iron-binding capacity
Időkeret: Baseline, 3 months, and 6 months
|
Change in total iron-binding capacity (TIBC) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in serum ferritin
Időkeret: Baseline, 3 months, and 6 months
|
Change in serum ferritin from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in transferrin saturation
Időkeret: Baseline, 3 months, and 6 months
|
Change in transferrin saturation (TSAT) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in serum vitamin B12
Időkeret: Baseline, 3 months, and 6 months.
|
Change in serum vitamin B12 level from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in erythropoietin
Időkeret: Baseline, 3 months, and 6 months.
|
Change in serum erythropoietin (EPO) level from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in hemoglobin
Időkeret: Baseline, 3 months, and 6 months.
|
Change in hemoglobin (Hb) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in hematocrit
Időkeret: Baseline, 3 months, and 6 months.
|
Change in hematocrit (Hct) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in red blood cell count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in red blood cell (RBC) count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in mean corpuscular volume
Időkeret: Baseline, 3 months, and 6 months.
|
Change in mean corpuscular volume (MCV) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in mean corpuscular hemoglobin
Időkeret: Baseline, 3 months, and 6 months.
|
Change in mean corpuscular hemoglobin (MCH) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in mean corpuscular hemoglobin concentration
Időkeret: Baseline, 3 months, and 6 months.
|
Change in mean corpuscular hemoglobin concentration (MCHC) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in red cell distribution width
Időkeret: Baseline, 3 months, and 6 months.
|
Change in red cell distribution width (RDW-CV) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in white blood cell count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in white blood cell (WBC) count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in lymphocyte count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in lymphocyte count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in neutrophil count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in neutrophil count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in eosinophil count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in eosinophil count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in basophil count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in basophil count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in monocyte count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in monocyte count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in platelet count
Időkeret: Baseline, 3 months, and 6 months.
|
Change in platelet (PLT) count from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in HOMA-IR
Időkeret: Baseline, 3 months, and 6 months
|
Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in fasting blood glucose
Időkeret: Baseline, 3 months, and 6 months
|
Change in fasting blood glucose (FBG) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in total cholesterol
Időkeret: Baseline, 3 months, and 6 months
|
Change in total cholesterol (TC) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in triglycerides
Időkeret: Baseline, 3 months, and 6 months
|
Change in triglycerides (TG) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months
|
|
Longitudinal change in low-density lipoprotein cholesterol
Időkeret: Baseline, 3 months, and 6 months.
|
Change in low-density lipoprotein cholesterol (LDL-C) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in high-density lipoprotein cholesterol
Időkeret: Baseline, 3 months, and 6 months.
|
Change in high-density lipoprotein cholesterol (HDL-C) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
|
Longitudinal change in body mass index
Időkeret: Baseline, 3 months, and 6 months.
|
Change in body mass index (BMI) from baseline through 3 months and 6 months during the study intervention.
|
Baseline, 3 months, and 6 months.
|
Együttműködők és nyomozók
Szponzor
Publikációk és hasznos linkek
Általános kiadványok
- Greibe E, Trolle B, Bor MV, Lauszus FF, Nexo E. Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome. Nutrients. 2013 Jul 5;5(7):2475-82. doi: 10.3390/nu5072475.
- Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends Endocrinol Metab. 2012 Oct;23(10):509-15. doi: 10.1016/j.tem.2012.04.003. Epub 2012 May 10.
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Urogenitális betegségek
- Nemi szervek betegségei
- Endokrin rendszer betegségei
- Neoplazmák
- Női urogenitális betegségek
- Női urogenitális betegségek és terhességi szövődmények
- Anyagcsere-betegségek
- Nemi szervek betegségei, nő
- Glükóz anyagcserezavarok
- Petefészek betegségek
- Adnexális betegségek
- Gonád rendellenességek
- Hiperinzulinizmus
- Petefészek ciszták
- Ciszták
- Táplálkozási és anyagcsere-betegségek
- Policisztás petefészek szindróma
- Inzulinrezisztencia
- Szerves vegyi anyagok
- Biguanidok
- Guanidinek
- Amidinok
- Metformin
Egyéb vizsgálati azonosító számok
- Metformin-Placebo-2026
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
az Egyesült Államokban gyártott és onnan exportált termék
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .